OSTXOS Therapies Inc同业对比
OS Therapies Inc 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OSTX本股 | $80M#7 | — | — | — | — | -223.7%#15 | — | — | — | — | -21.6%#7 | — |
| CTOR | $89M#2 | — | 2.2x#3 | — | — | -17.1%#10 | — | -61.3%#3 | — | — | -48.3%#12 | — |
| ANIX | $91M#1 | — | 6.3x#8 | 431.2x#4 | 0.0%#3 | 13.0%#5 | -5571.9%#5 | -75.5%#4 | -87.0%#3 | — | -27.2%#8 | — |
| EMMA | $84M#3 | — | — | 6.8x#3 | -25.2%#5 | -16.1%#9 | 1.9%#2 | — | — | 4#3 | — | — |
| MAIA | $84M#4 | — | 4.1x#7 | — | — | 3.7%#6 | — | -108.3%#8 | — | — | -13.8%#6 | — |
| ALDX | $84M#5 | — | 2.2x#4 | — | — | 39.4%#3 | — | -89.3%#5 | — | — | -71.9%#14 | — |
| ACET | $84M#6 | — | 0.7x#1 | — | — | 0.3%#8 | — | -97.2%#7 | — | — | -31.6%#10 | — |
| FBIO | — | 0.9x#1 | — | — | 9.7%#2 | 76.2%#2 | -111.0%#4 | 22.5%#1 | — | — | -27.9%#9 | — |
| TELO | $80M#8 | — | 15.8x#10 | — | — | 37.0%#4 | — | -206.9%#11 | — | — | -10.8%#5 | — |
| LNAI | $79M#9 | 1.1x#2 | — | 2413.1x#7 | -47.8%#6 | -101.3%#14 | -576678.5%#8 | — | — | 5#2 | -85.0%#15 | — |
| LFVN | $77M#11 | 15.4x#3 | 2.3x#5 | 0.4x#1 | -20.1%#4 | -48.3%#13 | 3.3%#1 | 15.1%#2 | 28.2%#1 | 6#1 | -40.6%#11 | 3.0%#1 |
| VRCA | $78M#10 | — | 18.1x#11 | 2.2x#2 | 370.2%#1 | 76.6%#1 | -34.2%#3 | -415.6%#12 | -36.1%#2 | — | -2.8%#4 | — |
| NTHI | $77M#12 | — | — | 1923.0x#6 | -51.8%#7 | -422.3%#16 | -145637.5%#7 | — | — | — | -70.6%#13 | — |
| PMVP | $76M#13 | — | 1.1x#2 | — | — | -32.0%#11 | — | -108.7%#9 | — | — | 17.4%#2 | — |
| GANX | $75M#14 | — | 6.6x#9 | 1360.4x#5 | -58.4%#8 | 1.2%#7 | -33908.5%#6 | -178.5%#10 | — | — | 6.2%#3 | — |
| CING | $74M#15 | — | 3.2x#6 | — | — | -35.6%#12 | — | -95.7%#6 | — | — | 29.4%#1 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议